$LXRX
LEXICON PHARMACEUTICALS, INC.

2024 Q4 Form 10-Q Financial Statement

#000106282224000060 Filed on November 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $1.750M
YoY Change 980.25%
Cost Of Revenue $71.00K
YoY Change 914.29%
Gross Profit $1.679M
YoY Change 983.23%
Gross Profit Margin 95.94%
Selling, General & Admin $39.59M
YoY Change 22.85%
% of Gross Profit 2358.07%
Research & Development $25.78M
YoY Change 46.83%
% of Gross Profit 1535.44%
Depreciation & Amortization $126.0K
YoY Change 26.0%
% of Gross Profit 7.5%
Operating Expenses $65.37M
YoY Change 31.31%
Operating Profit -$63.69M
YoY Change 28.33%
Interest Expense -$4.562M
YoY Change -217.0%
% of Operating Profit
Other Income/Expense, Net $4.562M
YoY Change 51.81%
Pretax Income -$64.81M
YoY Change 28.34%
Income Tax
% Of Pretax Income
Net Earnings -$64.81M
YoY Change 28.28%
Net Earnings / Revenue -3703.49%
Basic Earnings Per Share -$0.18
Diluted Earnings Per Share -$0.18
COMMON SHARES
Basic Shares Outstanding 361.5M shares 361.5M shares
Diluted Shares Outstanding 361.5M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $258.4M
YoY Change 18.29%
Cash & Equivalents $34.55M
Short-Term Investments $223.8M
Other Short-Term Assets $6.706M
YoY Change 56.28%
Inventory $636.0K
Prepaid Expenses
Receivables $2.895M
Other Receivables $0.00
Total Short-Term Assets $268.6M
YoY Change 20.25%
LONG-TERM ASSETS
Property, Plant & Equipment $2.135M
YoY Change 0.05%
Goodwill $44.54M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $828.0K
YoY Change 11.44%
Total Long-Term Assets $52.52M
YoY Change -1.11%
TOTAL ASSETS
Total Short-Term Assets $268.6M
Total Long-Term Assets $52.52M
Total Assets $321.1M
YoY Change 16.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $14.20M
YoY Change 17.99%
Accrued Expenses $21.85M
YoY Change 8.01%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $36.05M
YoY Change 11.73%
LONG-TERM LIABILITIES
Long-Term Debt $99.90M
YoY Change 0.64%
Other Long-Term Liabilities $6.670M
YoY Change 23.52%
Total Long-Term Liabilities $106.6M
YoY Change 7.36%
TOTAL LIABILITIES
Total Short-Term Liabilities $36.05M
Total Long-Term Liabilities $106.6M
Total Liabilities $142.6M
YoY Change 4.12%
SHAREHOLDERS EQUITY
Retained Earnings -$1.933B
YoY Change 12.6%
Common Stock $363.0K
YoY Change 48.16%
Preferred Stock
YoY Change
Treasury Stock (at cost) $4.615M
YoY Change 59.97%
Treasury Stock Shares
Shareholders Equity $178.5M
YoY Change
Total Liabilities & Shareholders Equity $321.1M
YoY Change 16.15%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$64.81M
YoY Change 28.28%
Depreciation, Depletion And Amortization $126.0K
YoY Change 26.0%
Cash From Operating Activities -$53.62M
YoY Change 28.89%
INVESTING ACTIVITIES
Capital Expenditures $307.0K
YoY Change 207.0%
Acquisitions
YoY Change
Other Investing Activities $53.78M
YoY Change -236.83%
Cash From Investing Activities $53.47M
YoY Change -236.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -916.0K
YoY Change 358.0%
NET CHANGE
Cash From Operating Activities -53.62M
Cash From Investing Activities 53.47M
Cash From Financing Activities -916.0K
Net Change In Cash -1.066M
YoY Change -98.69%
FREE CASH FLOW
Cash From Operating Activities -$53.62M
Capital Expenditures $307.0K
Free Cash Flow -$53.93M
YoY Change 29.32%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
5130000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
268606000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
176547000 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1961000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4538000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2135000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1987000 usd
CY2024Q3 us-gaap Goodwill
Goodwill
44543000 usd
CY2023Q4 us-gaap Goodwill
Goodwill
44543000 usd
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2304147 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
361492295 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34551000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22465000 usd
CY2024Q3 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
9000 usd
CY2024Q3 us-gaap Revenues
Revenues
1750000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
148000 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3444000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-64811000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-50525000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-49631000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q4 us-gaap Liabilities
Liabilities
136319000 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000 shares
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
Lexicon Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Address Address Line2
EntityAddressAddressLine2
11th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
The Woodlands
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei City Area Code
CityAreaCode
281
dei Local Phone Number
LocalPhoneNumber
863-3000
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
dei Trading Symbol
TradingSymbol
LXRX
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
223818000 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
147561000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5011000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5524000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
828000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
828000 usd
CY2024Q3 us-gaap Assets
Assets
321123000 usd
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
99508000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
142611000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
229429000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1741000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4451000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
438000 usd
CY2023Q3 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
14000 usd
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
76000 usd
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
64000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
268000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
15000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25780000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17558000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
57795000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44125000 usd
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
39592000 usd
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
65443000 usd
us-gaap Costs And Expenses
CostsAndExpenses
168907000 usd
us-gaap Costs And Expenses
CostsAndExpenses
125515000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-63693000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-164380000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-125013000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5330000 usd
us-gaap Net Income Loss
NetIncomeLoss
-166637000 usd
us-gaap Net Income Loss
NetIncomeLoss
-127363000 usd
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
363020303 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
363000 usd
CY2024Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
1528008 shares
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
867973 shares
CY2024Q3 us-gaap Treasury Stock Value
TreasuryStockValue
4615000 usd
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
2885000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
178512000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
93110000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
321123000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
244925000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
244925000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
213112000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
213112000 shares
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
288867000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4859000 usd
dei Amendment Flag
AmendmentFlag
false
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77381
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
us-gaap Other Expenses
OtherExpenses
7680000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1010000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
636000 usd
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
6706000 usd
CY2023Q4 us-gaap Assets
Assets
229429000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
14201000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
14389000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21845000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17157000 usd
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6670000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
245000 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2115891000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1862558000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1933476000 usd
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001062822
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
76-0474169
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2895000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5265000 usd
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
245792668 shares
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
36046000 usd
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
99895000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
381000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
31546000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-127048000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
117124000 usd
CY2024Q3 us-gaap Other Expenses
OtherExpenses
4562000 usd
us-gaap Other Expenses
OtherExpenses
11721000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9464000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
361492000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
306109000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
306109000 shares
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
542000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
315000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3415000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
0 usd
CY2023Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
824000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
265000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
88046000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
307000 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
75000 shares
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
0 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
139034000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-44904000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
63000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
186361000 usd
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
71000 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7000 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
32228000 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
49793000 usd
CY2023Q3 us-gaap Other Expenses
OtherExpenses
3899000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3005000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
318000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-64269000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
349000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
31000 usd
CY2023Q3 us-gaap Revenues
Revenues
162000 usd
us-gaap Revenues
Revenues
4527000 usd
us-gaap Revenues
Revenues
502000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
110844000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
81375000 usd
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
361492000 shares
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-13000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-50538000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-166319000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3815000 usd
dei Entity Address Address Line1
EntityAddressAddressLine1
2445 Technology Forest Blvd.
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1766839000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-31934000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3898000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-50525000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-13000 usd
CY2023Q3 us-gaap Stockholders Equity Other
StockholdersEquityOther
211000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
139510000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
93110000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4302000 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
241575000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
88000 usd
CY2024Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
1730000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-48397000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-81000 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-175000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
1000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-53429000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-143000 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
239980000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2801000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-64811000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
542000 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
178512000 usd
us-gaap Net Income Loss
NetIncomeLoss
-166637000 usd
us-gaap Net Income Loss
NetIncomeLoss
-127363000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
409000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
407000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
11962000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
11128000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1444000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1156000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
7418000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3613000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-481000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1885000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
290000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
255000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
336000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1576000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1935000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-513000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-389000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5673000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
9108000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-157289000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-111349000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
557000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
470000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
302921000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
223241000 usd
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
234400000 usd
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
121870000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-69078000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-101841000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
89000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
138823000 usd
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
241400000 usd
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
0 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1730000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
824000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
49962000 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-1306000 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
238453000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
187961000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
12086000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-25229000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22465000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46345000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34551000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21116000 usd
us-gaap Interest Paid Net
InterestPaidNet
9794000 usd
us-gaap Interest Paid Net
InterestPaidNet
6767000 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
115000 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 usd
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
0 usd
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
307000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span></div>
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
14800000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
58500000 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0 usd
CY2024Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
34551000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
223818000 usd
CY2024Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
258369000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
22465000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
147561000 usd
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
170026000 usd
CY2024Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
103000 usd
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
0 usd
CY2024Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
83000 usd
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
100000 usd
CY2024Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
450000 usd
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
281000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
636000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
381000 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4096000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6525000 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1961000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4538000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2135000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1987000 usd
CY2024Q3 lxrx Accrued Research And Development Services Current
AccruedResearchAndDevelopmentServicesCurrent
7878000 usd
CY2024Q3 lxrx Accrued Research And Development Services Current
AccruedResearchAndDevelopmentServicesCurrent
7878000 usd
CY2023Q4 lxrx Accrued Research And Development Services Current
AccruedResearchAndDevelopmentServicesCurrent
3705000 usd
CY2023Q4 lxrx Accrued Research And Development Services Current
AccruedResearchAndDevelopmentServicesCurrent
3705000 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11167000 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11167000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9591000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9591000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1301000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1301000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1291000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1291000 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1499000 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1499000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2570000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2570000 usd
CY2024Q3 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
21845000 usd
CY2024Q3 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
21845000 usd
CY2023Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
17157000 usd
CY2023Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
17157000 usd
us-gaap Severance Costs1
SeveranceCosts1
3400000 usd
us-gaap Payments For Postemployment Benefits
PaymentsForPostemploymentBenefits
1900000 usd
CY2024Q3 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
1500000 usd
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
99900000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5000000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5500000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4700000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5300000 usd
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
400000 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
400000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000 usd
us-gaap Payments For Rent
PaymentsForRent
1000000 usd
us-gaap Payments For Rent
PaymentsForRent
500000 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y8M12D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.096 rate
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.096 rate
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
345000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1220000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
865000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
881000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
898000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
4746000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
8955000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2977000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
5978000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1301000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4677000 usd
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2800000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3900000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12000000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11100000 usd
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000 shares
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
0001062822-24-000060-index-headers.html Edgar Link pending
0001062822-24-000060-index.html Edgar Link pending
0001062822-24-000060.txt Edgar Link pending
0001062822-24-000060-xbrl.zip Edgar Link pending
exh311certificationofprinc.htm Edgar Link pending
exh312certificationofprinc.htm Edgar Link pending
exh321certificationofprinc.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
lxrx-20240930.htm Edgar Link pending
lxrx-20240930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
lxrx-20240930_cal.xml Edgar Link unprocessable
lxrx-20240930_def.xml Edgar Link unprocessable
lxrx-20240930_lab.xml Edgar Link unprocessable
lxrx-20240930_htm.xml Edgar Link completed
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
lxrx-20240930_pre.xml Edgar Link unprocessable